Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $24 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and maintained a price target of $24.
July 18, 2023 | 8:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Arcutis Biotherapeutics and maintained a price target of $24.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $24 price target indicates a positive outlook for Arcutis Biotherapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100